Announcement PDF RNS Number : 9339N N4 Pharma PLC 28 November 2024 28 November 2024 N4 Pharma plc ("N4 Pharma" or the "Company") Grant of Options N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, announces that, on 27 November 2024, the Board granted 15 million options (the "Options") over ordinary shares of 0.4p each in the Company to certain directors of N4 Pharma as follows: Director Number of options granted Nigel Theobold (Chief Executive Officer) Michael Palfreyman (Non-Executive Director) Dr Chris Britten (Non-Executive Chairman) Luke Cairns (Executive Director) 6,000,000 3,000,000 3,000,000 3,000,000 The Options have an exercise price of 0.75p and vest in three equal tranches on the first, second and third anniversaries from the date of grant. The Options have a term of ten years from the date of grant. The FCA notifications, made in accordance with the requirements of the Market Abuse Regulation, are appended below. For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Via N4 Pharma Investor Hub Engage with us directly at N4 Pharma Investor Hub Sign up atinvestors.n4pharma.com SP Angel CorporateFinance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44(0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope Tel: +44(0)20 3657 0050 About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics. N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market. For further information on the Company visitwww.n4pharma.comor sign up atinvestors.n4pharma.com. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 1 a) 2 a) b) 3 a) b) 4 a) Details of the person discharging managerial responsibilities / person closely associated Name Nigel Theobold Reason for the notification Position/status Chief Executive Officer Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name N4 Pharma plc LEI 213800I841D2RKMFK955 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Options over Ordinary Shares of 0.4p each financial instrument, type of instrument Identification code (ISIN) for N4 Pharma plc ordinary shares: Identification code GB00BYW8QM32 b) Nature of the transaction c) Price(s) and volume(s) d) e) f) 1 a) 2 a) b) 3 a) b) 4 a) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Issue of options over ordinary shares of 0.4p each Price(s) Volume(s) 0.75p exercise price 6,000,000 n/a 27 November 2024 Outside a trading venue Details of the person discharging managerial responsibilities / person closely associated Name Michael Palfreyman Reason for the notification Position/status Non-Executive Director Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name N4 Pharma plc LEI 213800I841D2RKMFK955 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Options over Ordinary Shares of 0.4p each financial instrument, type of instrument Identification code Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32 b) Nature of the transaction c) Price(s) and volume(s) d) e) f) 1 a) 2 a) b) 3 a) b) 4 a) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction c) Price(s) and volume(s) f) 1 a) 2 a) b) 3 a) Volume(s) 0.75p exercise price 3,000,000 n/a 27 November 2024 Outside a trading venue Reason for the notification Position/status Non-Executive Chairman Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name N4 Pharma plc LEI 213800I841D2RKMFK955 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Options over Ordinary Shares of 0.4p each financial instrument, type of instrument Identification code (ISIN) for N4 Pharma plc ordinary shares: Identification code GB00BYW8QM32 Nature of the transaction e) Price(s) Details of the person discharging managerial responsibilities / person closely associated Name Dr Chris Britten b) d) Issue of options over ordinary shares of 0.4p each Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Issue of options over ordinary shares of 0.4p each Price(s) Volume(s) 0.75p exercise price 3,000,000 n/a 27 November 2024 Outside a trading venue Details of the person discharging managerial responsibilities / person closely associated Name Luke Cairns Reason for the notification Position/status Executive Director Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name N4 Pharma plc b) 4 a) LEI 213800I841D2RKMFK955 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Options over Ordinary Shares of 0.4p each financial instrument, type of instrument Identification code Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32 b) Nature of the transaction Issue of options over ordinary shares of 0.4p each c) Price(s) and volume(s) d) e) f) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Price(s) Volume(s) 0.75p exercise price 3,000,000 n/a 27 November 2024 Outside a trading venue This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHEAEFXAEDLFAA